LiPlasome Pharma Competitors and Similar CompaniesClear all
LiPlasome Pharma's competitors and similar companies include Sunesis Pharmaceuticals, Omeros, ARIAD Pharmaceuticals and Iovance Biotherapeutics.
 Sunesis Pharmaceuticals Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  ARIAD Pharmaceuticals ARIAD Pharmaceuticals is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. |  Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. | ||
Founding Date | Founding Date 2002 | Founding Date 1987 | Founding Date 1994 | Founding Date 1991 | Founding Date 2013 |
Type | Type Subsidiary | Type Subsidiary | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Hørsholm, DK HQ | Locations South San Francisco, US HQ | Locations Seattle, US HQ | Locations Cambridge, US HQ Boston, US Chicago, US Cincinnati, US Dallas, US Minneapolis, US New York, US see more | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US |
Employees | Employees 13 | Employees 42 | Employees 1968% decrease | Employees 1381% decrease | Employees 14868% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 248.6 m | Valuation ($) N/A | Valuation ($) 3.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $118.8m (FY, 2015) | Revenue (est.) $164.1m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $2.1m (FY, 2015) | Cost of goods $124m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $116.7m (FY, 2015) | Gross profit $40.1m (FY, 2024) |
Net income | Net income N/A | Net income ($114.8m) (FY, 2021) | Net income ($156.8m) (FY, 2024) | Net income ($231.2m) (FY, 2015) | Net income ($372.2m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 8m | Total funding raised $ 171.7m | Total funding raised $ 354.8m | Total funding raised N/A | Total funding raised $ 100m |
For sources of this data, please see the company profile
View Company Profiles
Sunesis Pharmaceuticals
HQ
South San Francisco, US
Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.
View companyOmeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View companyARIAD Pharmaceuticals
HQ
Cambridge, US
ARIAD Pharmaceuticals is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers.
View companyIovance Biotherapeutics
HQ
San Carlos, US
Employees
148
Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes.
View company